MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Dividend Yield on December 30, 2024: 0.00%

MoonLake Immunotherapeutics Dividend Yield is 0.00% on December 30, 2024, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

MoonLake Immunotherapeutics 52-week high Dividend Yield is 0.00% on December 30, 2024, which is 0.00% below the current Dividend Yield.
MoonLake Immunotherapeutics 52-week low Dividend Yield is 0.00% on December 30, 2024, which is 0.00% below the current Dividend Yield.
MoonLake Immunotherapeutics average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years